The JRC has now released a new CRM to aid the fight against beta-thalassemia. This genetic blood disorder reduces the production of hemoglobin, the iron-containing protein in red blood cells carrying ...

In a world first, medical regulators in the UK have approved a gene therapy that aims to cure two blood disorders. The treatment for sickle cell disease and beta thalassemia is the first to be ...

Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia. When the normal DNA sequence in an individual changes or mutates it can cause ...

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...

The JRC has now released a new CRM to aid the fight against beta-thalassemia. This genetic blood disorder reduces the production of haemoglobin, the iron-containing protein in red blood cells ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

Understanding the genetic underpinnings of each type guides diagnosis and treatment strategies. While alpha Thalassemia is quite uncommon in India but beta thalassemia is pretty common and ...

So far, Vertex has set up 45 authorized treatment centers for the gene-editing therapy and is ... in December and subsequent January nod in beta thalassemia. As Vertex looks to tap into the ...

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Editas Medicine is pivoting once again, announcing ...